The "Comprehensive In vitro Proarrhythmia Assay" (CiPA) 
Introduction
Computational modeling has proven to be a vital tool in cardiac arrhythmia research, and it is expected to be instrumental in the future pipelines for drug safety assessment. Indeed, the Comprehensive in vitro Proarrhythmia Assay (CiPA) initiative seeks to introduce a new cardiac drug safety testing paradigm that combines in vitro drug effects on multiple ion channels, computational modeling of cardiac currents and AP, and the use of human stem-cell derived cardiomyocytes [1, 2] .
In the present outlook, it is crucial to choose a model which will preserve an immediate and direct relationship to experimentally derived and verifiable data sets. Nowadays the "gold standard" in the in silico human ventricular cellular electrophysiology is the O'Hara-Rudy model (ORd) [3] . However, since models will always be approximations of the "real world", it is necessary to constantly develop and improve them, depending on the specific question to address. For example, a modified version of the ORd model with a novel formulation for the human ether-à-go-go-related (hERG) ionic current that can reproduce temperature-induced changes in major channel gating processes, and optimised for drug testing, has been recently developed by the US Food and Drug Administration [4] .
Another ] o increases lengthen APD, and viceversa.
The work of Passini & Severi [5] , which is our starting point, has replaced the original I CaL Hodgkin-Huxley description, in the ORd model, by a new Markov model, similar to the one used by Decker-Rudy for canine epicardial cells [6] . In that new model, the APD- [Ca 2+ ] o dependence was improved and corrected without altering model behaviour in control conditions, as similarly done for older models in previous works [7, 8] .
On the other hand, the steady state action potential duration (APD) rate dependency and the S1S2 APD restitution protocols were not well replicated by that model. For this reason, this work proposes an upgrade of the model presented in [5] , which preserves the correct APD- [Ca 2+ ] o dependence and is able to fit the experimental data of both rate dependence and restitution protocol. 
Computing in

Methods
The O'Hara-Rudy human ventricular AP [3] model was chosen for this study because of the large number of human ventricular experimental data obtained from more than 140 hearts used in its construction and evaluation, and its choice within the CiPA initiative [1] .
First of all, the L-Type Ca 2+ current has been inherited from Passini & Severi [5] where a Markov model description was used. With respect to this previous work, we have slightly modified the values of some parameters: rates in the CDI (Ca 2+ -dependent inactivation) loop versus VDI (voltage-dependent inactivation) loop are less faster than in [5] and one kinetic rate is increased ( , ). Moreover, the n gate kinetics were defined with the algebraic resolution of the differential equations (fast enough to be assumed in steady state) which described the interaction between Ca 2+ and Calmodulin (CaM) bound to L-type Ca 2+ -channels (eq. 1).
In order to preserve the achieved APD- [Ca 2+ ] o dependence without altering the model behaviour in control conditions and to gain a good fitting of the steady state APD rate dependency and the S1S2 APD restitution experimental data, an optimization procedure was implemented to refine the model. In particular, a set of parameters, which are involved in the APD rate dependence and APD- [Ca 2+ ] o dependence, underwent an optimization procedure using the lsqnonlin built-in Matlab function with a cost function taking into account the differences between the experimental and simulated data of the steady state APD rate dependence (for BCL = 400, 1000, 2000 ms), the S1S2 APD restitution (S2=10, 20, 30, 40, 50, 70, 100, 150, 200, 500 ms) and a term to control the APD- [Ca 2+ ] o dependence. Since experimental evidence is not clear about Ca 2+ movement inside the sarcoplasmic reticulum (SR) [9] , the SR was reduced to a single compartment (with a consequent rescaling in the cell geometry), instead of the separation between Network SR (NSR) and Junctional SR (JSR), like some other human models [10, 11] Finally we have included in this new model the I Kr Markovian formulation from Li et al. [12] and replaced the SR calcium release equations with a description similar to the one presented in Paci et al. [13] .
Other changes involved: -speed up of Ca 2+ diffusion from subsarcolemma space to cytoplasm; -increase of SERCA pump maximal current; -increase of Na + /Ca 2+ exchanger maximal current; -increase of Na + /K + ATPase maximal current; -increase of Ca 2+ background maximal current; -reduction of L-type Ca 2+ channel permeability; -increase of late sodium maximal current; -increase of I Kr maximal current; -reduction of inward rectifier potassium maximal current and increase of the instantaneous rectification slope. Model differential equations were implemented in Matlab (Mathworks Inc., Natick, MA, USA) and solved with a variable order solver (ode15s), based on numerical differentiation formulas [14] . Simulations were run with the original and modified models at variable [Ca 2+ ] o in the range 0.9 -2.4 mM. Pacing was maintained until steady state AP was reached (1000 s) and APD X was measured once membrane voltage reached X% of the resting value (as in [3] ).
Results
Model Validation
The present model has been validated against the same experimental data proposed for the original ORd model, and the results were compared with both the corresponding experimental data and the original ORd model.
The I CaL Markov model has been validated, in the previous work [5] , against the experimental voltageclamp data used for the original one, in order to verify consistency between the two models in control conditions.
The inverse relationship between APD and [Ca
2+
] o was correctly reproduced as shown in Figure 1 ] o transfer within the various cell compartments is still debated. We also optimised the maximal conductance of other currents, which play a role in these protocols.
4.
Discussion and Conclusions
When setting [K + ] o = 4mM the experimental data of the S1S2 protocol and of the steady-state rate dependence were very well fitted with all the APD values for almost all the tested rates being within the experimental ranges Finally, this study highlights the importance of reproducing experimental conditions as closely as possible in the simulations to allow an effective comparison between experiments and simulations for validation.
The next steps will be the verification of the dynamic restitution protocol, relevant in particular for the study of alternans occurrence and the effects of drug block on APD rate dependence, in line with the work of Dutta et al. [15] and for using the new model in the CiPA scenario.
